Read by QxMD icon Read


Iman El Sayed, Adel Zaki, Akram M Fayed, Gihan M Shehata, Sherif Abdelmonem
Traumatic brain injury is a major problem worldwide. Our objective is to synthesize available evidence in the literature concerning the effectiveness of neuroprotective drugs (cerebrolysin, citicoline, and piracetam) on Glasgow outcome score (GOS), cognitive performance, and survival in traumatic brain injury patients. Comprehensive search of electronic databases, search engines, and conferences proceedings; hand search journals; searching reference lists of relevant articles, theses, and local publications; and contact of authors for incomplete data were performed...
August 18, 2016: Neurosurgical Review
Edward Rockenstein, Paula Desplats, Kiren Ubhi, Michael Mante, Jazmin Florio, Anthony Adame, Stefan Winter, Hemma Brandstaetter, Dieter Meier, Herbert Moessler, Eliezer Masliah
Neuronal stem cell (NSC) grafts have been investigated as a potential neuro-restorative therapy in Parkinson's disease (PD) but their use is compromised by the death of grafted cells. We investigated the use of Cerebrolysin (CBL), a neurotrophic peptide mixture, as an adjunct to NSC therapy in the α-synuclein (α-syn) transgenic (tg) model of PD. In vehicle-treated α-syn tg mice, there was decreased survival of NSCs. In contrast, CBL treatment enhanced the survival of NSCs in α-syn tg groups and ameliorated behavioral deficits...
2015: Journal of Experimental Neuroscience
David Calderón Guzmán, Norma Osnaya Brizuela, Maribel Ortíz Herrera, Ernestina Hernández García, Gerardo Barragán Mejía, Hugo Juárez Olguín, Armando Valenzuela Peraza, Jonas Attilus, Norma Labra Ruíz
The study tested the hypothesis that cerebrolysin protects the brain from free radicals in rats treated with 3-nitropropionic acid (3-NPA). To address this hypothesis, the levels of dopamine (DA) and some oxidative stress biomarkers were measured after administration of 3-NPA. Young male Fischer rats were treated for three days with cerebrolysin, 3-NPA or both substances. Their brains were extracted, and DA, lipid peroxidation (LP), glutathione (GSH), calcium, and H2O2 were measured using validated methods...
September 1, 2016: Acta Pharmaceutica
S V Berezhnaya, E Z Yakupov, Yu A Zakharov
OBJECTIVE: To study the impact of combination therapy with mexidol and cerebrolysin on the clinical status of patients with chronic cerebral ischemia (CCI), II stage, in ambulatory conditions. MATERIAL AND METHODS: The study included 36 patients with CCI, II stage. In addition to basic therapy, patients received two courses of the mexidol/cerebrolysin combination during 6 weeks with 3 month-interval between the courses. The dynamics of subjective complaints of the patients and objective clinical signs was assessed after each course...
2016: Zhurnal Nevrologii i Psikhiatrii Imeni S.S. Korsakova
Neveen A Noor, Haitham S Mohammed, Iman M Mourad, Yasser A Khadrawy, Heba S Aboul Ezz
AIMS: Parkinson's disease (PD) is the second most prevalent neurodegenerative disease affecting the population. The present study investigates the potential therapeutic effect of cerebrolysin (CBL), as a neurotrophic factor mimic, on the behavioral and biochemical alterations induced in 6-hydroxydopamine (6-OHDA) - lesioned rats as a model of PD. MAIN METHODS: The animals were divided into 3 experimental groups; control group, Parkinsonian model group through bilateral microinjection of 6-OHDA into substantia nigra (SN) and CBL-treated group which received a daily intraperitoneal administration of CBL (2...
June 15, 2016: Life Sciences
X Anton Alvarez, Irene Alvarez, Olalla Iglesias, Ignacio Crespo, Jesus Figueroa, Manuel Aleixandre, Carlos Linares, Elias Granizo, Manuel Garcia-Fantini, Jose Marey, Eliezer Masliah, Stefan Winter, Dafin Muresanu, Herbert Moessler
BACKGROUND: Low circulating brain derived neurotrophic factor may promote cognitive deterioration, but the effects of neurotrophic and combination drug therapies on serum brain derived neurotrophic factor were not previously investigated in Alzheimer's disease. METHODS: We evaluated the effects of Cerebrolysin, donepezil, and the combined therapy on brain derived neurotrophic factor serum levels at week 16 (end of Cerebrolysin treatment) and week 28 (endpoint) in mild-to-moderate Alzheimer's disease patients...
April 7, 2016: International Journal of Neuropsychopharmacology
Li-Xia Xue, Ting Zhang, Yu-Wu Zhao, Zhi Geng, Jing-Jiong Chen, Hao Chen
Cerebrolysin and DL-3-n-butylphthalide (NBP) have each shown neuroprotective efficacy in preclinical models of acute ischemic stroke (AIS) and passed clinical trials as therapeutic drugs for AIS. The present study was a clinical trial to assess and compare the efficacy and safety of NBP and Cerebrolysin in the reduction of neurological and behavioral disability following AIS. A randomized, double-blind trial was conducted with enrolment of 60 patients within 12 h of AIS. In addition to routine treatment, patients were randomly assigned to receive a 10-day intravenous administration of NBP, Cerebrolysin or placebo...
May 2016: Experimental and Therapeutic Medicine
Carlos Solis-Gaspar, Ruben A Vazquez-Roque, Ma De Jesús Gómez-Villalobos, Gonzalo Flores
The spontaneously hypertensive (SH) rat has been used as an animal model of vascular dementia (VD). Our previous report showed that, SH rats exhibited dendritic atrophy of pyramidal neurons of the CA1 dorsal hippocampus and layers 3 and 5 of the prefrontal cortex (PFC) at 8 months of age. In addition, we showed that cerebrolysin (Cbl), a neurotrophic peptide mixture, reduces the dendritic atrophy in aged animal models. This study aimed to determine whether Cbl was capable of reducing behavioral and neuronal alterations, in old female SH rats...
September 2016: Synapse
O A Gromova, A G Kalacheva, T R Grishina, T E Bogacheva, V I Demidov, I Yu Torshin
AIM: To study an effect of cerebrolysin on the expression and severity of primary-generalized seizures caused by thiosemicarbazide and to analyze the corresponding molecular mechanisms. MATERIAL AND METHODS: The effects of cerebrolysin were studied on the thiosemicarbazide model of convulsions in 144 male rats. Cerebrolysin was introduced intraperitoneally in the dose of 2.5 ml/kg of body mass 5 days a week during 18 days. RESULTS AND CONCLUSION: Cerebrolysin reduces the severity and duration of seizures caused by thiosemicarbazide and increases the survival rate of animals...
2016: Zhurnal Nevrologii i Psikhiatrii Imeni S.S. Korsakova
Han-Yu Dong, Xin-Mei Jiang, Chun-Bo Niu, Lin Du, Jun-Yan Feng, Fei-Yong Jia
To examine the effects of Cerebrolysin on the treatment of diabetic peripheral neuropathy, we first established a mouse model of type 2 diabetes mellitus by administering a high-glucose, high-fat diet and a single intraperitoneal injection of streptozotocin. Mice defined as diabetic in this model were then treated with 1.80, 5.39 or 8.98 mL/kg of Cerebrolysin via intraperitoneal injections for 10 consecutive days. Our results demonstrated that the number, diameter and area of myelinated nerve fibers increased in the sciatic nerves of these mice after administration of Cerebrolysin...
January 2016: Neural Regeneration Research
A I Konoplya, V B Laskov, A A Shul'ginova
OBJECTIVE: To determine the dynamics of immunometabolic characteristics in patients with chronic ischemia of the brain (discirculatory encephalopathy - DE) under the influence of various combinations of neuroprotective and antioxidant drugs and on this basis to identify the most effective therapeutic combinations. MATERIAL AND METHODS: Authors analyzed the results of treatment of 57 patients with DE, stage II, comorbid to hypertension, stage II, which were divided into 3 groups that received comprehensive basic and advanced therapy with paired combinations of neuroprotective and antioxidant drugs...
2015: Zhurnal Nevrologii i Psikhiatrii Imeni S.S. Korsakova
L V Anosova, E A Levina, L S Chutko
OBJECTIVE: To study clinical/psychological characteristics in children with sensorineural hearing loss, IV degrees, before and after the cochlear implantation (CI) and to assess the dynamics of speech development during the rehabilitation using the neuroprotective drug cerebrolysin. MATERIAL AND METHODS: Authors examined 93 patients, aged from 5 to 8 years. The main group (n=46) received cerebrolysin, the control group was not treated with this drug. A diagnostic study included patient's history, neurological and neuropsychological examinations, auditory perception and sound reproduction...
2015: Zhurnal Nevrologii i Psikhiatrii Imeni S.S. Korsakova
A F Iznak, E V Iznak, Ya B Kalyn, T P Safarova, V S Sheshenin, S I Gavrilova
OBJECTIVE: To compare the changes in brain functional state in combined antidepressive treatment (venlafaxine plus cerebrolysin) vs. monotherapy with the same antidepressant in elderly depressive patients using quantitative EEG methods. MATERIAL AND METHODS: Forty patients, aged 60-79 years, mean 67.1±5.7) were randomized to two groups. Patients of group 1 were treated with venlafaxine (4 weeks, in dose of 75-150 mg/day). Patients of group 2 were additionally treated with cerebrolysin (totally 20 i/v infusions during 4 weeks, 20...
2016: Zhurnal Nevrologii i Psikhiatrii Imeni S.S. Korsakova
Won Hyuk Chang, Chang-hyun Park, Deog Young Kim, Yong-Il Shin, Myoung-Hwan Ko, Ahee Lee, Shin Yi Jang, Yun-Hee Kim
BACKGROUND: Cerebrolysin is a neuropeptide preparation with neuroprotective and neurorestorative effects. Combining Cerebrolysin treatment with a standardized rehabilitation program may have a potential synergistic effect in the subacute stage of stroke. This study aims to evaluate whether Cerebrolysin provides additional motor recovery on top of rehabilitation therapy in the subacute stroke patients with moderate to severe motor impairment. METHODS: This phase IV trial was designed as a prospective, multicenter, randomized, double-blind, placebo-controlled, parallel-group study...
2016: BMC Neurology
Li Zhang, Michael Chopp, Mei Lu, Talan Zhang, Stefan Winter, Edith Doppler, Dieter Meier, Li Chao, Anita Eapen, Pardeep Pabla, Zheng Gang Zhang
BACKGROUND: Cerebrolysin is a mixture of neuropeptides and free amino acids that is clinically used for the treatment of stroke. To further standardize treatment schemes, we assessed the dose response of Cerebrolysin on sensorimotor outcome in a rat model of ischemic stroke. METHODS: This study was a prospective, blinded, placebo-controlled, preclinical experiment. Male and female Wistar rats, subjected to embolic middle cerebral artery occlusion, were randomly treated with Cerebrolysin doses of 0...
April 2016: International Journal of Stroke: Official Journal of the International Stroke Society
Edward Rockenstein, Kiren Ubhi, Michael Mante, Jazmin Florio, Anthony Adame, Stefan Winter, Hemma Brandstaetter, Dieter Meier, Eliezer Masliah
BACKGROUND: Tauopathies are a group of neurodegenerative disorders with accumulation of three-repeat (3R) or four-repeat (4R) Tau. While 3R tau is found in Pick's disease and Alzheimer's disease (AD), 4R tau is more abundant in corticobasal degeneration, progressive supranuclear palsy, and AD. We have previously shown that Cerebrolysin™ (CBL), a neuropeptide mixture with neurotrophic effects, ameliorates the pathology in amyloid precursor protein transgenic (tg) mouse model of AD and 4R tau, however it is unclear if CBL ameliorates the deficits and neuropathology in the mouse model of Pick's disease over expressing 3R tau...
November 26, 2015: BMC Neuroscience
Dafin F Muresanu, Wolf-Dieter Heiss, Volker Hoemberg, Ovidiu Bajenaru, Cristian Dinu Popescu, Johannes C Vester, Volker W Rahlfs, Edith Doppler, Dieter Meier, Herbert Moessler, Alla Guekht
BACKGROUND AND PURPOSE: The aim of this trial was to investigate whether stroke patients who receive Cerebrolysin show improved motor function in the upper extremities at day 90 compared with patients who receive a placebo. METHODS: This study was a prospective, randomized, double-blind, placebo-controlled, multicenter, parallel-group study. Patients were treated with Cerebrolysin (30 mL/d) or a placebo (saline) once daily for 21 days, beginning at 24 to 72 hours after stroke onset...
January 2016: Stroke; a Journal of Cerebral Circulation
B R Martinez Sánchez, J J Hernández Hernandez, D I Franco Del Águila, E Gryzbowski Gainza, W C Paz Ballesteros, J Herrera Rojas, G Peniche Otero, Y Marroquín, L E Zambrano Velarde
No abstract text is available yet for this article.
November 2015: Value in Health: the Journal of the International Society for Pharmacoeconomics and Outcomes Research
A Kulikov, G Abdrashitova
No abstract text is available yet for this article.
November 2015: Value in Health: the Journal of the International Society for Pharmacoeconomics and Outcomes Research
A Kulikov, G Abdrashitova
No abstract text is available yet for this article.
November 2015: Value in Health: the Journal of the International Society for Pharmacoeconomics and Outcomes Research
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"